Changchun high-tech unit gets vaccine trial nod, company updates buyback

Changchun High & New Technology Industry Group announced its subsidiary, Changchun Boke Biological Technology Co., Ltd. (Boke Bio), has received approval for the clinical trial of its adsorbed acellular diphtheria, tetanus, acellular pertussis, and Haemophilus influenzae type b (bivalent) conjugate vaccine. The vaccine aims to prevent pertussis, diphtheria, tetanus, and invasive infections caused by Haemophilus influenzae type b in infants aged two months and older. The approval, dated October 9, 2025, positions the combined vaccine as a potential advancement in public health by offering multi-disease protection with fewer injections.

The bivalent vaccine combines Boke Bio's acellular DTP (tri-component) and lyophilized Hib conjugate vaccines. The acellular DTP vaccine is currently in Phase III clinical trials. The Hib vaccine has also received clinical trial approval, as previously announced on December 26, 2024.

In a separate development, the company updated on its share buyback program. As of September 30, 2025, Changchun High & New Technology Industry Group had repurchased 3,894,517 shares, representing 0.95% of its total share capital. The buyback involved a total transaction value of 399,999,400.76 yuan, with prices ranging from 84.00 yuan to 112.25 yuan per share. The company plans to continue its buyback program.